Jason N. Mock

Senior Counsel


Jason Mock is a senior counsel with Foley & Lardner LLP. He is a member of the firm’s Chemical, Biotechnology & Pharmaceutical, and Patent Office Trials Practice groups. Dr. Mock works with clients on a broad range of technologies including pharmaceuticals and biologics, diagnostics and medical devices, and formulations/delivery platforms. In addition to drafting and prosecuting patents, Dr. Mock is well versed in providing opinions on patentability, invalidity, and freedom-to-operate, and he has successfully represented both patent owners and petitioners in inter partes reviews before the Patent Trial and Appeal Board.

Dr. Mock began working at Foley & Lardner as a summer associate in 2014, and prior to that he worked as a technical specialist and patent agent.


Dr. Mock earned his law degree from The George Washington University Law School (J.D., with honors, 2016), where he was a member of the Federal Circuit Bar Journal. He was a George S. Hastings IP Scholar and was awarded the Finnegan Prize for Intellectual Property Law. He earned a doctorate in pharmaceutical and biomedical science from the University of Georgia (Ph.D., summa cum laude, 2012). Dr. Mock earned bachelor’s degrees in biotechnology and agricultural and applied economics, also from the University of Georgia (B.S., magna cum laude, 2008). 

Admissions and Professional Memberships

Dr. Mock is admitted to practice law in Washington, D.C. and Virginia, as well as before the United States Patent and Trademark Office.


  • J. Mock, T. Yan, and K. Sharon, "IPR proactive defense measures - strategies and considerations for patent owners," PTAB Trial Insights (May 2016)
  • J. Mock, "Split Federal Circuit Upholds Constitutionality of Single PTAB Panels Rendering Both Institution & Final Written Decisions," PTAB Trial Insights (January 2016)
  • J. Mock, "Post-Grant Proceedings at the USPTO and the Rising Tide of Federal Circuit Appeals," The Federal Circuit Bar Journal (September 2015)
  • J. Mock, L. Choi, and K. Schorr, "The Road Ahead for Kyle Bass's IPRs," Law360 (August 2015)
  • J. Mock, L. Choi, and K. Schorr, "Will New PTAB Rules Impact IPRs Filed by Kyle Bass Hedge Fund?" The National Law Review (August 2015)
  • A. Baluch and J. Mock, “Survey of State Laws Against Bad-Faith Patent Assertion,” Bloomberg BNA Patent, Trademark & Copyright Journal (August 2014)
  • J. Mock and N. Quach, et al., “Role of the Phospholipase A2 Receptor in Liposome Drug Delivery in Prostate Cancer Cells,” Mol. Pharmaceuticals (2014)
  • J. Mock, et al., “Evidence for Distinct Mechanisms of Uptake and Antitumor Activity of Secretory Phospholipase A2 Responsive Liposomes in Prostate Cancer,” Integr. Biol. (2012)
  • J. Mock, et al., “Haloenol Pyranones and Morpholinones as Antineoplastic Agents of Prostate Cancer,” Bioorg. and Med. Chem. Letters (2012)
  • J. Mock, et al., “Secretory Phospholipase A2 Responsive Liposomes,” J. Pharm. Sci. (2011)
  • J. Mock, et al., Enhanced Antitumor Activity of Low-Dose Continuous Administration Schedules of Topotecan in Prostate Cancer,” Cancer Bio. and Therapy (2011)


PTAB’s Motion to Amend Pilot Program: Review of Initial Results
19 August 2020
PTAB Trial Insights
COVID-19: Patent Procurement and Licensing
31 March 2020
Life Sciences Intellectual Property Review
While Tempting, PTAB Requests for Rehearing Face Long Odds
15 October 2019
PTAB Trial Insights
Federal Circuit Breathes More Life Into Divided Infringement
16 January 2018